ClinicalTrials.gg

Program

TS-172

A development code. Also written as “TS-172 20~60 mg/day”, “'TS-172 20~60 mg/day” and “TS-172 20 mg”.

Its studies are mostly in Hyperphosphatemia, led by Taisho Pharmaceutical.

Furthest: phase 3, since Dec 17, 202414 company-led studies, 4 open or runningNext primary completion: Nov 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Taisho Pharmaceutical144 open or runningphase 3since Dec 17, 2024Jul 5, 2021Nov 30, 2026phase 3 · NCT07548840

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 5, 2021First study: phase 1 study in Healthy Adult SubjectsFirst studyNCT04979572 · 41 enrolled · Japan
  2. Jan 12, 2023Phase 2 study in Hyperphosphatemia Patients on HemodialysisNCT05699239 · 326 enrolled · Japan
  3. Sep 2, 2024Phase 1 study in Healthy Male SubjectsNCT06596356 · 6 enrolled · Japan
  4. Dec 17, 2024Phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT06745531 · 101 enrolled · Japan
  5. Dec 17, 2024Phase 2 study in Hyperphosphatemia Patients on HemodialysisNCT06745518 · 62 enrolled · Japan
  6. Feb 16, 20253 phase 1 studiesNCT06849778, NCT06837155, NCT06837142
  7. Jul 17, 2025Phase 1 study in Healthy Adult Male SubjectsNCT07084961 · 16 enrolled · Japan
  8. Nov 13, 2025Phase 1 study in Patients With Mild or Moderate Hepatic ImpairmentNCT07231029 · 25 enrolled · Japan
  9. Nov 24, 2025Phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT07285304 · 300 planned · Japan
  10. Dec 3, 2025Phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT07285291 · 100 planned · Japan
  11. Apr 16, 20262 phase 3 studiesNCT07548853, NCT07548840

Ahead

  1. Nov 30, 2026Primary completion: phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT07548840
  2. Dec 22, 2026Primary completion: phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT07285291
  3. May 31, 2027Primary completion: phase 3 study in Hyperphosphatemia Patients on Peritoneal DialysisNCT07548853
  4. Jul 31, 2027Primary completion: phase 3 study in Hyperphosphatemia Patients on HemodialysisNCT07285304

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07548853Hyperphosphatemia Patients on Peritoneal Dialysis · Japan3RecruitingMay 31, 202730
NCT07548840Hyperphosphatemia Patients on Hemodialysis · Japan3Active, not recruitingNov 30, 202634
NCT07285291Hyperphosphatemia Patients on Hemodialysis · Japan3RecruitingDec 22, 2026100
NCT07285304Hyperphosphatemia Patients on Hemodialysis · Japan3RecruitingJul 31, 2027300
NCT07231029Patients With Mild or Moderate Hepatic Impairment · Japan1CompletedOct 21, 202625
NCT07084961Healthy Adult Male Subjects · Japan1CompletedSep 11, 202516
NCT06849778Patients on Hemodialysis · Japan1CompletedApr 24, 20257
NCT06837155Healthy Volunteers · Japan1CompletedMay 20, 202552
NCT06837142Healthy Male Subjects · Japan1CompletedApr 30, 202530
NCT06745531Hyperphosphatemia Patients on Hemodialysis · Japan3CompletedOct 13, 2025101
NCT06745518Hyperphosphatemia Patients on Hemodialysis · Japan2CompletedJul 15, 202562
NCT06596356Healthy Male Subjects · Japan1CompletedOct 28, 20246
NCT05699239Hyperphosphatemia Patients on Hemodialysis · Japan2CompletedDec 26, 2023326
NCT04979572Healthy Adult Subjects · Japan1CompletedJan 26, 202241

How it is read

Names in the registry

  • “TS-172”, 7 entries
  • “TS-172 20~60 mg/day”, 3 entries
  • “'TS-172 20~60 mg/day”, 1 entry
  • “TS-172 20 mg”, 1 entry
  • “TS-172 90 mg”, 1 entry

Codes read as this program: TS172.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.